MFDS Approves AbbVie's Migraine Prevention Drug 'Aqupta Tablets'

On the 15th, the Ministry of Food and Drug Safety announced the approval of the imported new drug from Korea AbbVie, 'Aqupta Tablets (active ingredient Atogepant)' 10mg and 60mg, used for migraine prevention.

AbbVie's migraine preventive medication 'Acupta (North American name Qulipta)'

Aqupta selectively blocks the calcitonin gene-related peptide (CGRP) receptor, a receptor that mediates intracellular signaling related to inflammation and immune responses, thereby preventing migraines. CGRP is known as a vasodilatory neurotransmitter that causes migraine headaches along with the dilation of the middle cerebral artery.

Aqupta Tablets are the first oral CGRP antagonist developed with this mechanism and were previously approved by the U.S. Food and Drug Administration (FDA) in April and the European Medicines Agency (EMA) in August. The Ministry of Food and Drug Safety stated, "Aqupta Tablets are expected to help expand the options for migraine prevention drugs for adult migraine patients."